CD19 Antibody (CB19) - Azide and BSA Free

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-80634

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
NBP2-80634
Print Quote
Bulk Order
Forumulation
Catalog #
BSA Free
NBP2-25196
View Product
100% Guarantee

Key Product Details

Species Reactivity

Validated:

Human, Mouse

Applications

CyTOF-ready, Flow Cytometry, Immunocytochemistry/ Immunofluorescence, In vitro assay, Western Blot

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 Clone # CB19

Format

Azide and BSA Free

Concentration

1 mg/ml

View all CD19 Antibodies »

Product Summary for CD19 Antibody (CB19) - Azide and BSA Free

Immunogen

Intact normal human B cell cells were used as immunogen to generate the CB19 clone.

Epitope

The exact CD19 epitope recognized by the antibody has not been mapped and is unknown.

Reactivity Notes

Mouse reactivity reported in scientific literature (PMID: 27532872).

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Scientific Data Images for CD19 Antibody (CB19) - Azide and BSA Free

Immunocytochemistry/ Immunofluorescence: CD19 Antibody (CB19) - Azide and BSA Free [NBP2-80634]

Immunocytochemistry/ Immunofluorescence: CD19 Antibody (CB19) - Azide and BSA Free [NBP2-80634]

Immunocytochemistry/Immunofluorescence: CD19 Antibody (CB19) - Azide and BSA Free [NBP2-80634] - The CD19 (CB19) antibody was tested in Daudi cells at a 1:40 dilution against Dylight 488 (Green). Actin and nuclei were counterstained against Phalloidin 568 (Red) and DAPI (Blue), respectively. Image from the standard format of this antibody.
Flow Cytometry: CD19 Antibody (CB19) - Azide and BSA Free [NBP2-80634]

Flow Cytometry: CD19 Antibody (CB19) - Azide and BSA Free [NBP2-80634]

Flow Cytometry: CD19 Antibody (CB19) - Azide and BSA Free [NBP2-80634] - Analysis using the PE conjugate of NBP2-25196. Staining of CD19 in 1x10^6 human PBMC using 10 ul (0.25 ug) of was used to test this product. Propidium iodide negative lymphocyte population gated for analysis.
Flow Cytometry: CD19 Antibody (CB19) - Azide and BSA Free [NBP2-80634]

Flow Cytometry: CD19 Antibody (CB19) - Azide and BSA Free [NBP2-80634]

Flow Cytometry: CD19 Antibody (CB19) - Azide and BSA Free [NBP2-80634] - A surface stain was performed on human peripheral blood lymphocytes with CD9 (HI9a) antibody NB100-77915AF647 and a matched isotype control NBP2-27287AF488. Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature. A co-stain was performed with NBP2-26646. Image from the standard format of this antibody.
View 6 more images

Applications for CD19 Antibody (CB19) - Azide and BSA Free

Application
Recommended Usage

Flow Cytometry

0.2 ug/10^6 cells

Immunocytochemistry/ Immunofluorescence

1:25-1:100

In vitro assay

reported in scientific literature (PMID 9576485)

Western Blot

reported in scientific literature (PMID 17327405)
Application Notes
This antibody is CyTOF ready.
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein G purified

Formulation

PBS

Format

Azide and BSA Free

Preservative

No Preservative

Concentration

1 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: CD19

CD19 (Cluster of Differentiation 19), also known as B-lymphocyte surface antigen B4, is a type 1 transmembrane glycoprotein belonging to immunoglobulin (Ig) subfamily that serves as a biomarker for normal and neoplastic B cells (1,2). CD19 is a co-receptor for the B cell receptor (BCR) signaling complex and has a critical role in regulating B cell signaling and immune response (1,2). The CD19 protein contains an extracellular N-terminus containing two C2 Ig-like domains separated by a helical non-Ig domain, a single pass transmembrane domain, and a highly conserved cytoplasmic C-terminal domain (1,2). The human CD19 protein, encoded by the CD19 gene located on chromosome 16p11.2, is 556 amino acids (aa) in length with a calculated theoretical molecular weight (MW) of 61 kDa and an observed molecular weight of 95 kDa (1-3). CD19 associates with other molecules - CD21, CD81, and CD225 - to form the BCR co-complex, also called the CD19 complex, through CD21 binding to the complement C3d complex (1-3). Complement C3d bridges the BCR with the CD19 complex into lipid rafts of the plasma membrane (1-3). CD19 is capable of modulating B cell development through both BCR-dependent and -independent signaling (1-3). Upon BCR activation, the tyrosine residues of CD19's cytoplasmic tail recruits multiple kinases including Lyn, Vav, and PI3K, amplifying BCR-mediated immune signaling and B cell activation (1-3).

Considering the role of CD19 in BCR signaling and its expression in development from pre-B cells through plasma cells, it is understandable that CD19 dysfunction and abnormal expression is associated with numerous B cell malignancies and autoimmune disorders (1-5). CD19 expression is typically observed at relatively normal levels in B cell acute lymphoblastic leukemia (B-ALL) and chronic lymphoblastic leukemia (CLL) but is often reduced other types of lymphoma including diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) (1,2). On the other hand, CD19 expression is typically increased in autoimmune disorders such as systemic sclerosis (SSc) and multiple sclerosis (MS) as modeled by experimental autoimmune encephalomyelitis (EAE) (2). CD19 has become a therapeutic molecular target for the treatment of B cell lymphomas and autoimmune disorders using monoclonal antibodies (mAbs), bi-specific T cell engaging (BiTE) antibodies, and CD19-specific chimeric antigen receptor (CAR) T cells (1,2,4-6). Although anti-CD19 CAR T cell therapy has become the standard for the treatment of B cell malignancies, patients may experience relapse due to resistance mechanisms (6). Strategies to improve efficacy and limit relapse include combination of CAR T cell therapy with immune checkpoint inhibitors like anti-PD-1 (4,6).

References

1. Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012;1(1):36. https://doi.org/10.1186/2162-3619-1-36

2. Li X, Ding Y, Zi M, et al. CD19, from bench to bedside. Immunol Lett. 2017;183:86-95. https://doi.org/10.1016/j.imlet.2017.01.010

3. Wentink MWJ, van Zelm MC, van Dongen JJM, Warnatz K, van der Burg M. Deficiencies in the CD19 complex. Clin Immunol. 2018;195:82-87. https://doi.org/10.1016/j.clim.2018.07.017

4. Frigault MJ, Maus MV. State of the art in CAR T cell therapy for CD19+ B cell malignancies. J Clin Invest. 2020;130(4):1586-1594. https://doi.org/10.1172/JCI129208

5. Penack O, Koenecke C. Complications after CD19+ CAR T-Cell Therapy. Cancers (Basel). 2020;12(11):3445. https://doi.org/10.3390/cancers12113445

6. Bouziana S, Bouzianas D. Anti-CD19 CAR-T cells: Digging in the dark side of the golden therapy. Crit Rev Oncol Hematol. 2021;157:103096. https://doi.org/10.1016/j.critrevonc.2020.103096

Alternate Names

CD19, CVID3, Leu-12

Gene Symbol

CD19

Additional CD19 Products

Product Documents for CD19 Antibody (CB19) - Azide and BSA Free

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for CD19 Antibody (CB19) - Azide and BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.